Elite Pharmaceuticals, Inc.
ELTP
$0.26
$0.00-1.08%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 200.44% | 8.61% | 270.71% | 224.16% | -1,055.62% |
| Total Depreciation and Amortization | -3.01% | -5.46% | 3.59% | -7.66% | -9.02% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | -95.98% | -67.80% | -185.27% | -137.01% | 837.05% |
| Change in Net Operating Assets | 136.13% | 70.90% | -451.63% | -70.68% | -654.28% |
| Cash from Operations | -31.85% | 133.45% | -396.23% | 250.38% | 369.89% |
| Capital Expenditure | -270.76% | 47.22% | -- | -11.80% | 71.97% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -270.76% | 47.22% | -- | -686.93% | 86.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 97.13% | 23.16% | 35.89% | 16.90% | -2,261.75% |
| Issuance of Common Stock | -- | 306.74% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 97.23% | 69.71% | 82.60% | 63.67% | -2,261.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -12.28% | 187.65% | -339.06% | 323.38% | 698.21% |